암종양유전자 SETDB1과 FosB 발현에 대한 p53의 음성 조절기작

국문 초록 (Abstract)

암세포에 항암제를 처리하게 되면, 세포증식, 이동성 또는 약물 내성과 관련된 많은 유전자들의 발현 변화가 발생하며, 유전자 발현 변화는 상호간의 조절 네트워크에 의해 밀접하게 연결될 수도 있다고 추측된다. 본 연구에서 p53 유전자 유무가 다른 A549와 H1299 인간 폐암세포에 독소루비신을 처리하면, 원종양유전자인 FosB의 발현은 증가하지만, 원종양유전자인 SETDB1의 발현은 감소하지만, 단백질 발현의 양적인 차이가 발생한다는 사실을 알 수 있었다. TF motif binding 분석 프로그램을 이용하여 SETDB1과 FosB 프로모터지역에서의 p53단백질의 결합가능성을 분석한 결과, SETDB1의 경우 18부위, FosB의 경우 21 부위의 p53 결합부위를 예측할 수 있었다. SETDB1과 FosB 프로모터의 subcloning하여 luciferase 분석을 수행한 결과, p53은 SETDB1과 FosB을 음성적으로 조절한다는 사실을 알 수 있었다. 또한, H1299 세포에 p53의 과발현은 SETDB1 과 FosB의 발현을 감소시킬 수 있음을 RT-PCR, western blot, qPCR, 면역염색 실험을 통해 확인하였다. 이러한 결과를 종합하여 본다면, p53에 의한 SETDB1과 FosB 유전자 발현 조절은 항암제 처리과정에서 나타나는 암세포의 사멸과 생존에 대한 기능적 조절 네트워크로 사료된다.

다국어 초록 (Multilingual Abstract)

Treatment with anticancer drugs changes the expression of multiple genes related to cell proliferation, migration, and drug resistance. These changes in gene expression may be connected to regulatory networks for each other. This study showed that doxorubicin treatment induces the expression of oncogenic FosB and decreases the expression of oncogenic SETDB1 in A549 and H1299 human lung cancer cells, which are different in tumor suppressor p53 status. However, a small difference was detected in the quantitative expression of those proteins in the two kinds of cells. To examine the potential regulation of SETDB1 and FosB by p53, we predicted putative p53 binding sites on the genomic DNA of SETDB1 and FosB using a TF motif binding search program. These putative p53 binding sites were identified as 18 sites in the promoter regions of SETDB1 and 21 sites in the genomic DNA of FosB. A luciferase assay confirmed that p53 negatively regulated the promoter activities of SETDB1 and FosB. Furthermore, the results of RT-PCR, western blot, qPCR, and immunostaining experiments indicated that the transfection of exogenous p53 decreases the expression of SETDB1 and FosB in H1299 cells. This indicates that p53 negatively regulates the expression of SETDB1 and FosB at the transcriptional level. Collectively, the downregulation of SETDB1 and FosB by p53 may provide functional networks for apoptosis and for the survival of cancer cells during anticancer drug treatment.

목차 (Table of Contents)

• 서론
• 재료 및 방법
• 결과
• 고찰
• References
• 초록

참고문헌 (Reference)

1 김근철, "생물정보 프로그램을 활용한 SETDB1 유전자 프로모터 클로닝" 한국생명과학회 24 (24): 1-7, 2014

2 나한흠, "사람 핵DNA로부터 FosB 유전자 프로모터 클로닝 및 활성도 분석" 한국생명과학회 27 (27): 857-863, 2017

3 Williams, A. B., "p53 in the DNAdamage-repair process" 6 : 10-, 2016

4 Noh, H. J., "p53 down-regulates SETDB1 gene expression during paclitaxel induced-cell death" 446 : 43-48, 2014

5 Muller, M., "p53 activates the CD95(APO-1/Fas)gene in response to DNA damage by anticancer drugs" 188 : 2033-2045, 1998

6 Liu, S., "miR-144-3p Targets FosB Proto-oncogene, AP-1 Transcription Factor Subunit(FOSB)to suppress proliferation, migration, and invasion of PANC1 pancreatic cancer cells" 26 : 683-690, 2018

7 Surget, S., "Uncovering the role of p53 splice variants in human malignancy : a clinical perspective" 7 : 57-68, 2013

8 Miyashita, T., "Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo" 9 : 1799-1805, 1994

9 Li, T., "Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence" 149 : 1269-1283, 2012

10 Michael, D., "The p53–Mdm2 module and the ubiquitin system" 13 : 49-58, 2003

11 Han, E. S., "The in vivo gene expression signature of oxidative stress" 34 : 112-126, 2008

12 Ceol, C. J., "The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset" 471 : 513-517, 2011

13 Toufektchan, E., "The guardian of the genome revisited : p53 downregulates genes required for telomere maintenance, DNA repair, and centromere structure" 10 : 135-, 2018

14 Nestler, E. J., "The addicted brain" 290 : 78-85, 2004

15 Barrett, C. S., "TGF-βeffects on prostate cancer cell migration and invasion require FosB" 77 : 72-81, 2017

16 Shahzad, M. M., "Stress effects on FosB-and interleukin-8(IL8)-driven ovarian cancer growth and metastasis" 285 : 35462-35470, 2010

17 Sun, Q., "SETDB1accelerates tumourigenesis by regulating the WNT signalling pathway" 235 : 559-570, 2015

18 Han-Heom Na, "SETDB1 mediated FosB expression increases the cell proliferation rate during anticancer drug therapy" 생화학분자생물학회 49 (49): 238-243, 2016

19 Wisdom, R., "Proto-oncogene FosB : the amino terminus encodes a regulatory function required for transformation" 13 : 2635-2643, 1993

20 Donehower, L. A., "Phosphatases reverse p53-mediated cell cycle checkpoints" 111 : 7172-7173, 2014

21 Seoane, J., "Myc suppression of the p21 Cip1 Cdk inhibitor influences the outcome of the p53 response to DNA damage" 419 : 729-734, 2002

22 Ruffle, J. K., "Molecular neurobiology of addiction : what’s all the(Δ)FosB about? Am" 40 : 428-437, 2014

23 Nestler, E. J., "Molecular mechanisms of drug addiction" 47 : 24-32, 2004

24 Aubrey, B. J., "How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression?" 25 : 104-113, 2018

25 Sun, Y., "Histone methyltransferase SETDB1is required for prostate cancer cell proliferation, migration and invasion" 16 : 319-324, 2014

26 Fei, Q., "Histone methyltransferase SETDB1 regulates liver cancer cell growth through methylation of p53" 6 : 1-12, 2015

27 Wu, P. C., "H3K9 histone methyltransferase, KMT1E/SETDB1, cooperates with the SMAD2/3 pathway to suppress lung cancer metastasis" 74 : 7333-7343, 2014

28 Bamberger, A., "Expression pattern of the AP 1 family in breast cancer : Association of fosB expression with a well differentiated, receptor positive tumor phenotype" 84 : 533-538, 1999

29 Xu, H., "EZH2 inhibitors-mediated epigenetic reactivation of FOSB inhibits triple-negative breast cancer progress" 20 : 175-, 2020

30 Lee, J., "DZNep, inhibitor of S-adenosylhomocysteine hydrolase, down-regulates expression of SETDB1H3K9me3 HMTase in human lung cancer cells" 438 : 647-652, 2013

31 Fridman, J. S., "Control of apoptosis by p53" 22 : 9030-9040, 2003

32 Nihira, N. T., "Acetylation-dependent regulation of MDM2 E3 ligase activity dictates its oncogenic function" 10 : 1126-, 2017

33 Guo, J., "AKT methylation by SETDB1 promotes AKT kinase activity and oncogenic functions" 21 : 226-237, 2019

34 Siderovski, D. P., "A set of human putative lymphocyte G0/G1switch genes includes genes homologous to rodent cytokine and zinc finger protein-encoding genes" 9 : 579-587, 1990